文献速递妇科生殖医学

子宫内膜瘤患者接受内分泌子宫内膜异位症治疗不足

Endometrioma patients are under-treated with endocrine endometriosis therapy.
PubMed 文献 · Hum Reprod · 2025-01-01

这项观察性横断面多中心研究纳入838例有痛经和/或子宫内膜异位症的绝经前女性,通过2023年5月至11月的回顾性在线调查收集数据。结果显示,子宫内膜瘤患者当前接受内分泌治疗的比例为42.5%,显著低于其他类型子宫内膜异位症患者的52.1%。

要点

  • 子宫内膜瘤患者当前内分泌治疗比例为42.5%,低于其他子宫内膜异位症患者的52.1%。
  • 手术确诊子宫内膜异位症患者当前激素治疗比例为49.0%,高于无手术确诊者的34.3%。
  • 子宫内膜瘤患者过去接受激素治疗的比例为73.9%,低于其他类型患者的84.3%。

核心结论

  • 子宫内膜瘤患者接受内分泌子宫内膜异位症治疗的比例显著低于其他类型子宫内膜异位症患者。
  • 结果表明患者常无合理医学理由拒绝内分泌子宫内膜异位症治疗。

研究设计与样本

  • 观察性横断面多中心研究,纳入838例有痛经和/或子宫内膜异位症的绝经前女性,平均年龄30.7±6.9岁(范围15-54岁)。
  • 数据通过2023年5月至11月的回顾性在线调查收集,参与者来自2017年1月至2023年3月就诊于两家大学医院子宫内膜异位症中心的患者及德国子宫内膜异位症协会网站和社交媒体招募。

主要发现

  • 无手术确诊子宫内膜异位症亚组(n=277)中95例(34.3%)当前接受内分泌治疗,手术确诊亚组(n=561)中275例(49.0%)当前接受激素治疗,手术确诊者显著更常接受内分泌治疗(F=16.587,P<0.001)。
  • 子宫内膜瘤患者(n=254,占手术确诊患者的45.2%)当前接受激素治疗的比例为42.5%(n=113),显著低于其他类型子宫内膜异位症患者(n=261)的52.1%(n=139)(F=3.976,P=0.047)。
  • 子宫内膜瘤患者过去接受激素治疗的比例为73.9%(n=187),显著低于其他类型患者的84.3%(n=220)(F=8.297,P=0.004)。
  • 比较子宫内膜瘤患者与其他类型患者拒绝内分泌治疗的各种原因,未发现统计学差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究受回顾性设计和患者报告结局的在线问卷限制。
  • 研究的自愿性质和在线招募可能导致选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Is there a difference in the use of endocrine endometriosis therapy in endometriosis patients with and without endometrioma? SUMMARY ANSWER: Patients with endometriomas received significantly less endocrine endometriosis treatment (present intake in 42.5%) compared to patients with other forms of endometriosis and without endometriomas (present intake in 52.1%). WHAT IS KNOWN ALREADY: Endocrine endometriosis therapy in patients with endometriomas reduces the risk of recurrence and therefore the risk of further surgery and subsequent irreversible damage to ovaries which results into reduced antral follicle counts (AFC), anti-Mullerian hormone levels (AMH), and early menopause. However, there is evidence of increasing rejection of endocrine endometriosis treatment in this population. STUDY DESIGN, SIZE, DURATION: A total of 838 premenopausal woman with dysmenorrhea and/or endometriosis (mean age 30.7 ± 6.9 years, range 15-54 years) were included in this observational cross-sectional multicenter study. Data including the extent of dysmenorrhea, prevalence of other comorbidities like migraine with aura and migraine never with aura, diagnosis of endometriosis, history of endometriosis surgery, and hormone therapy, were collected in a retrospective online survey from May to November 2023. PARTICIPANTS/MATERIALS, SETTING, METHODS: Patients visiting two university hospital endometriosis centers between January 2017 and March 2023, and with available email address, were invited for study participation by email in May 2023. Further recruitment of participants was achieved through the website and social medial channels of the German Endometriosis Association. Participation in the online survey was open between May and November 2023. MAIN RESULTS AND THE ROLE OF CHANCE: In the subgroup of women (with dysmenorrhea) without surgically confirmed endometriosis (SCE) (n = 277), 95 (34.3%) were currently undergoing endocrine treatment for dysmenorrhea and contraceptional purposes. On the contrary, in the subgroup of patients with SCE (n = 561), 275 (49.0%) were currently undergoing hormonal treatment. Subjects with SCE therefore significantly more commonly took endocrine treatment (F = 16.587, P < 0.001) compared to those without SCE. Endometriomas were present in 254 patients (45.2% of all SCE patients), and these patients were significantly less likely to have used hormonal treatment (i) in the present and (ii) in the past (i. n = 113 42.5%, ii. n = 187, 73.9%) compared to patients with other forms of endometriosis (n = 261) (i. n = 139, 52.1%, ii. n = 220, 84.3%) (i. F = 3.976, P = 0.047, ii. F = 8.297, P = 0.004). Various reasons for rejection of endocrine endometriosis treatment were analyzed, when comparing endometrioma subjects to patients with other types of endometriosis, but no statistical differences were found. LIMITATIONS, REASONS FOR CAUTION: This study is limited by its retrospective design and an online questionnaire with patient-reported outcomes. A selection bias due to the voluntary nature of the study and the online recruitment is also possible. WIDER IMPLICATIONS OF THE FINDINGS: The results show that patients often refuse endocrine endometriosis treatments without a rational medical reason. According to the literature, this unnecessarily exposes these patients to a higher risk for endometrioma recurrence and subsequently a higher risk of repeat surgery and permanent damage to ovarian function. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by the University of Luebeck (budget for university teaching and research). A.C. was supported by DFG (CRC/TR 296 'Local control of TH action', LocoTact, P07) and by funds of University of Luebeck, medical section (LACS01-2024). N.B. was supported by the DFG (BR4328.2-1, GRK1957), the Michael J Fox Foundation, the Collaborative Center for X-linked Dystonia-Parkinsonism and the EU Joint Programme-Neurodegenerative Disease Research (JPND). C.C., H.G., C.G., I.A., A.K., A.R. received no funding for this study. There were no competing interests. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Cirkel C, Göbel H, Göbel C, et al. Endometrioma patients are under-treated with endocrine endometriosis therapy. Hum Reprod. 2025. PMID: 39579221. doi:10.1093/humrep/deae257

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。